Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2022

04-07-2022 | Neuroblastoma | Pediatric Oncology

Letter to the Editor: Reflections on “Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma”

Authors: Haoru Wang, MD, Xin Chen, MD, Ling He, MD

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Excerpt

We read with great interest the recent article by Mansfield et al.1 on the impact of neoadjuvant chemotherapy on image-defined risk factors (IDRFs) in high-risk neuroblastoma. First, we would like to congratulate the authors for their in-depth and detailed study of the changes of IDRFs to induction chemotherapy in children with neuroblastoma, which is also our research interest. In our recent, unpublished study, induction chemotherapy did effectively improve IDRFs in neuroblastoma, as the authors pointed out. However, it would be interesting to consider the primary anatomical site or sympathetic nerve chain origin of the tumor when analyzing the effect of induction chemotherapy on IDRFs in neuroblastoma in future studies, rather than studying the changes of IDRFs to chemotherapy in general. …
Literature
1.
Mansfield SA, McCarville MB, Lucas JT Jr, et al. Impact of neoadjuvant chemotherapy on image-defined risk factors in high-risk neuroblastoma. Ann Surg Oncol. 2022;29(1):661–70.CrossRefPubMed
2.
Vo KT, Matthay KK, Neuhaus J, et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014;32(28):3169–76.CrossRefPubMed
3.
Oldridge DA, Truong B, Russ D, et al. Differences in genomic profiles and outcomes between thoracic and adrenal neuroblastoma. J Natl Cancer Inst. 2019;111(11):1192–201.CrossRefPubMed
4.
Brisse HJ, Blanc T, Schleiermacher G, et al. Radiogenomics of neuroblastomas: relationships between imaging phenotypes, tumor genomic profile and survival. PLoS One. 2017;12(9):e0185190.CrossRefPubMed
5.
Temple WC, Vo KT, Matthay KK, et al. Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma. Cancer Med. 2021;10(7):2232–41.CrossRefPubMed
6.
Delforge X, De Cambourg P, Defachelles AS, et al. Unresectable thoracic neuroblastic tumors: changes in image-defined risk factors after chemotherapy and impact on surgical management. Pediatr Blood Cancer. 2021;68(12):e29260.CrossRefPubMed
7.
Avanzini S, Pio L, Erminio G, et al. Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes. Pediatr Blood Cancer. 2017;64(11).
8.
Matthyssens LE, Nuchtern JG, Van De Ven CP, et al. A novel standard for systematic reporting of neuroblastoma surgery: The International Neuroblastoma Surgical Report Form (INSRF): a joint initiative by the Pediatric Oncological Cooperative Groups SIOPEN∗, COG∗∗, and GPOH∗∗∗. Ann Surg. 2022;275(3):e575–85.CrossRefPubMed
Metadata
Title
Letter to the Editor: Reflections on “Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma”
Authors
Haoru Wang, MD
Xin Chen, MD
Ling He, MD
Publication date
04-07-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12096-w

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue

Hepatobiliary Tumors

Surveillance Patterns for Hepatocellular Carcinoma among Screening-Eligible Patients in the Medicare Population

ASO Visual Abstract

ASO Visual Abstract: Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver

ASO Author Reflections

ASO Author Reflections: How Immunotherapy Could Change the Management of Responsive Solid Tumors

Pancreatic Tumors

Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver

Reconstructive Oncology

Impact of Patient Primary Language upon Immediate Breast Reconstruction After Mastectomy

ASO Author Reflections

ASO Author Reflections: Prognostic Factors in Gastrointestinal Extrapulmonary Small Cell Carcinoma Using Real-World Data